West Pharmaceutical Services (NYSE:WST) Price Target Raised to $500.00

West Pharmaceutical Services (NYSE:WST) had its price objective increased by investment analysts at TD Cowen from $420.00 to $500.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. TD Cowen‘s price objective would indicate a potential upside of 21.14% from the stock’s previous close.

Several other research analysts have also recently weighed in on WST. Barclays boosted their price target on West Pharmaceutical Services from $440.00 to $500.00 and gave the stock an “overweight” rating in a research note on Friday. Wall Street Zen lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Saturday, October 24th. UBS Group raised their price objective on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. BNP Paribas Exane initiated coverage on shares of West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 target price on the stock. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and an average target price of $402.83.

West Pharmaceutical Services Stock Down 0.9%

NYSE:WST traded down $3.94 during mid-day trading on Friday, hitting $412.73. 1,062,315 shares of the company’s stock were exchanged, compared to its average volume of 809,136. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The business has a fifty day moving average price of $366.60 and a 200 day moving average price of $312.50. West Pharmaceutical Services has a one year low of $223.83 and a one year high of $438.27. The company has a market cap of $29.05 billion, a PE ratio of 52.85, a P/E/G ratio of 2.83 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%. The company had revenue of $874.50 million for the quarter, compared to the consensus estimate of $827.12 million. During the same quarter in the prior year, the business posted $1.96 EPS. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. Equities analysts predict that West Pharmaceutical Services will post 8.92 EPS for the current year.

Insiders Place Their Bets

In related news, VP Annette Favorite sold 2,524 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the completion of the sale, the vice president owned 21,818 shares in the company, valued at $7,963,570. This trade represents a 10.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 15,659 shares of company stock worth $5,443,749. Company insiders own 0.60% of the company’s stock.

Institutional Trading of West Pharmaceutical Services

Institutional investors and hedge funds have recently made changes to their positions in the company. Cornerstone Planning Group LLC lifted its position in shares of West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 50 shares during the period. Avalon Trust Co purchased a new stake in West Pharmaceutical Services in the second quarter valued at about $28,000. Addison Advisors LLC acquired a new stake in West Pharmaceutical Services in the 2nd quarter worth approximately $28,000. Raiffeisen Bank International AG lifted its stake in shares of West Pharmaceutical Services by 95.6% during the second quarter. Raiffeisen Bank International AG now owns 133 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 65 shares during the period. Finally, Elevation Wealth Partners LLC increased its holdings in shares of West Pharmaceutical Services by 1,377.8% in the second quarter. Elevation Wealth Partners LLC now owns 133 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 124 shares during the period. 93.90% of the stock is currently owned by institutional investors.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

About West Pharmaceutical Services

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.